TY - JOUR
T1 - Neuraminidase gene homology contributes to the protective activity of influenza vaccines prepared from the influenza virus library
AU - Haredy, Ahmad M.
AU - Yamada, Hiroshi
AU - Sakoda, Yoshihiro
AU - Okamatsu, Masatoshi
AU - Yamamoto, Naoki
AU - Omasa, Takeshi
AU - Mori, Yasuko
AU - Kida, Hiroshi
AU - Okamoto, Shigefumi
AU - Okuno, Yoshinobu
AU - Yamanishi, Koichi
N1 - Publisher Copyright:
© 2014 The Authors.
PY - 2014/11/1
Y1 - 2014/11/1
N2 - Whole-virus (WV) vaccines from influenza A/duck/Hokkaido/77 (H3N2), and its reassortant strains H3N4, H3N5 and H3N7, which have the same haemagglutinin (HA) gene but different neuraminidase (NA) genes, were prepared from our influenza virus library. Mice were intranasally immunized with equivalent doses of each vaccine (1–0.01 mg per mouse). All of the mice that received the highest dose of each vaccine (1 mg per mouse) showed equivalent high HAinhibiting (HI) antibody titres and survived the H3N2 challenge viruses. However, mice that received lower doses of vaccine (0.1 or 0.01 mg per mouse) containing a heterologous NA had lower survival rates than those given the H3N2-based vaccine. The lungs of mice challenged with H3N2 virus showed a significantly higher virus clearance rate when the vaccine contained the homologous NA (N2) versus a heterologous NA, suggesting that NA contributed to the protection, especially when the HI antibody level was low. These results suggested that, even if vaccines prepared for a possible upcoming pandemic do not induce sufficient HI antibodies, WV vaccines can still be effective through other matched proteins such as NA.
AB - Whole-virus (WV) vaccines from influenza A/duck/Hokkaido/77 (H3N2), and its reassortant strains H3N4, H3N5 and H3N7, which have the same haemagglutinin (HA) gene but different neuraminidase (NA) genes, were prepared from our influenza virus library. Mice were intranasally immunized with equivalent doses of each vaccine (1–0.01 mg per mouse). All of the mice that received the highest dose of each vaccine (1 mg per mouse) showed equivalent high HAinhibiting (HI) antibody titres and survived the H3N2 challenge viruses. However, mice that received lower doses of vaccine (0.1 or 0.01 mg per mouse) containing a heterologous NA had lower survival rates than those given the H3N2-based vaccine. The lungs of mice challenged with H3N2 virus showed a significantly higher virus clearance rate when the vaccine contained the homologous NA (N2) versus a heterologous NA, suggesting that NA contributed to the protection, especially when the HI antibody level was low. These results suggested that, even if vaccines prepared for a possible upcoming pandemic do not induce sufficient HI antibodies, WV vaccines can still be effective through other matched proteins such as NA.
UR - http://www.scopus.com/inward/record.url?scp=84908277930&partnerID=8YFLogxK
U2 - 10.1099/vir.0.067488-0
DO - 10.1099/vir.0.067488-0
M3 - 学術論文
C2 - 25053564
AN - SCOPUS:84908277930
SN - 0022-1317
VL - 95
SP - 2365
EP - 2371
JO - Journal of General Virology
JF - Journal of General Virology
ER -